Skip to content

Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients

Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01226537
Enrollment
20
Registered
2010-10-22
Start date
2012-11-30
Completion date
2014-12-31
Last updated
2012-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either, Because the Body Does Not Produce Enough Insulin,, or Because Cells do Not Respond to the Insulin That, is Produced.

Keywords

Taurine,Diabetes mellitus,oxidative stress,glycemic control

Brief summary

Diabetes mellitus (DM) and its vascular complications are the one of the most prevalent diseases in the state of Qatar. It is a multifactorial disease associated with the development of retinopathy, nephropathy, neuropathy, cardiomyopathy, and severe vascular dysfunction. The complications of diabetes are caused by either insulin deficiency (type 1 DM) or insulin resistance (type II DM).Unfortunately, effective and sustainable prevention programs of diabetes are limited, and treatment options for type II DM are restricted. Current therapy is based upon control of blood glucose, cholesterol and triglycerides, primarily through insulin replacement in type I diabetes or oral hypoglycemic agents and/or insulin replacement in type II diabetes. New therapies able to prevent vascular complications of diabetes are needed to decrease the occurrence of end organ damage and improve the quality of life of the people. Safe and effective nutritional supplements that could be given along with the regular treatment of the patients that might reduce the need for insulin replacement therapy provide tighter glucose control and protect against oxidative stress and the vascular pathology associated with diabetes mellitus are the need of the hour. Our hypothesis is that supplementation of Taurine in the diets of diabetic patients might reduce the dose or need for insulin replacement therapy and protect them against oxidative stress that is responsible for the complications of diabetes mellitus.

Interventions

500 mg taurine capsules twice per day for 6 months

Sponsors

Hamad Medical Corporation
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Male or Female 2. Above 18-65 Years of old 3. Known diabetic patients with HbA1c\>8.0% 4. People who provide signed informed consent -

Exclusion criteria

* 1\. Pregnancy 2. Diabetic patients with HbA1c \<8.0 % 3. Recent or prospective surgical interventions 4. Complications of Type I and Type II DM, e.g., Active cardiovascular disease, nephropathy, retinopathy, neuropathy 5. People who do not provide signed informed consent

Design outcomes

Primary

MeasureTime frameDescription
Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin 7) Eye test9 months500mg Taurine capsules will be given twice per day for 6 months. After the medication, each month the following outcomes will be measured Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin

Contacts

Primary ContactShajitha Thekkeveetil, PhD
sveetil@hmc.org.qa00974-44395096
Backup ContactYousef Al Ansari, MD
yalansari@hmc.org.qa00974-2112754

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026